HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology (NASDAQ:CGON) and maintained a $75 price target.
May 06, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on CG Oncology, with a steady price target of $75.
The reiteration of a Buy rating and maintenance of a $75 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards CG Oncology. This endorsement may lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100